Earnings Summary

Eiger Biopharmaceuticals Inc’s revenue fell -20.25% since last year same period to $3.21Mn in the Q3 2023. On a quarterly growth basis, Eiger Biopharmaceuticals Inc has generated -30.89% fall in its revenue since last 3-months.

Eiger Biopharmaceuticals Inc’s net profit jumped 35.27% since last year same period to $-18.03Mn in the Q3 2023. On a quarterly growth basis, Eiger Biopharmaceuticals Inc has generated 12.88% jump in its net profits since last 3-months.

Eiger Biopharmaceuticals Inc’s net profit margin jumped 18.83% since last year same period to -561.86% in the Q3 2023. On a quarterly growth basis, Eiger Biopharmaceuticals Inc has generated -26.05% fall in its net profit margins since last 3-months.

Eiger Biopharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -7.5 - a 0% jump from last quarter’s estimates.

Eiger Biopharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -7.5.

Eiger Biopharmaceuticals Inc’s earning per share (EPS) jumped 33.87% since last year same period to -0.41 in the Q3 2023. This indicates that the Eiger Biopharmaceuticals Inc has generated 33.87% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Eiger Biopharmaceuticals Inc’s return on assets (ROA) stands at -0.52.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Eiger Biopharmaceuticals Inc’s return on equity (ROE) stands at -2.26.